Rider, JenniferFiorentino, MichelangeloKelly, RachelGerke, TravisJordahl, KristinaSinnott, JenniferGiovannucci, EdwardLoda, MassimoMucci, LoreleiFinn, Stephen2019-09-232015Rider, J. R., M. Fiorentino, R. Kelly, T. Gerke, K. Jordahl, J. A. Sinnott, E. L. Giovannucci, et al. 2015. “Tumor Expression of Adiponectin Receptor 2 and Lethal Prostate Cancer.” Carcinogenesis 36 (6): 639–47. https://doi.org/10.1093/carcin/bgv048.0143-33341460-2180http://nrs.harvard.edu/urn-3:HUL.InstRepos:41392159To investigate the role of adiponectin receptor 2 (AdipoR2) in aggressive prostate cancer we used immunohistochemistry to characterize AdipoR2 protein expression in tumor tissue for 866 men with prostate cancer from the Physicians' Health Study and the Health Professionals Follow-up Study. AdipoR2 tumor expression was not associated with measures of obesity, pathological tumor stage or prostate-specific antigen (PSA) at diagnosis. However, AdipoR2 expression was positively associated with proliferation as measured by Ki-67 expression quartiles (P-trend < 0.0001), with expression of fatty acid synthase (P-trend = 0.001), and with two measures of angiogenesis (P-trend < 0.1). An inverse association was observed with apoptosis as assessed by the TUNEL assay (P-trend = 0.006). Using Cox proportional hazards regression and controlling for age at diagnosis, Gleason score, year of diagnosis category, cohort and baseline BMI, we identified a statistically significant trend for the association between quartile of AdipoR2 expression and lethal prostate cancer (P-trend = 0.02). The hazard ratio for lethal prostate cancer for the two highest quartiles, as compared to the two lowest quartiles, of AdipoR2 expression was 1.9 (95% confidence interval [CI]: 1.2-3.0). Results were similar when additionally controlling for categories of PSA at diagnosis and Ki-67 expression quartiles. These results strengthen the evidence for the role of AdipoR2 in prostate cancer progression.en-USJournal Article2019-09-2310.1093/carcin/bgv048